Site-Specific PEGylation of G-CSF Polypeptides
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current G-CSF conjugates, such as PEGylated forms, exhibit heterogeneous PEGylation due to variable PEGylation levels, leading to difficulties in predicting biological activity and requiring daily administration for chemotherapy-induced neutropenia treatment.
Innovation Solution
Development of polypeptides with non-native cysteine residues at specific sites and short linker sequences for site-specific PEGylation, allowing for more controlled and homogeneous conjugation with PEG molecules, enhancing serum half-life and bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If conventional PEGylation methods are used to extend serum half-life, then duration of action is improved, but manufacturing precision deteriorates due to heterogeneous PEGylation
Solution Approach 1:
The patent introduces a specific cysteine residue at a defined position in the G-CSF polypeptide sequence, creating a localized reaction site for PEGylation. This ensures that PEG molecules attach only at this specific location rather than at multiple random sites, achieving homogeneous PEGylation while extending serum half-life through controlled conjugation
Solution Approach 2:
The patent modifies the polypeptide sequence by introducing a non-native cysteine residue, changing the chemical parameters of the molecule to enable site-specific PEGylation. This parameter change allows controlled conjugation with PEG molecules, achieving both extended duration of action and homogeneous product composition
2Manufacturing precision
If site-specific PEGylation is implemented to improve manufacturing precision, then ease of operation deteriorates due to additional sequence modifications
Solution Approach 1:
The patent separates the G-CSF polypeptide into functional regions, identifying a specific location where cysteine introduction will not interfere with the biologically active region. This segmentation allows the polypeptide to be modified at a non-critical site, maintaining ease of production while achieving site-specific PEGylation and homogeneous conjugation
Data Source
AI summary
The present disclosure relates to a polypeptide exhibiting granulocyte-colony stimulating factor activity. The polypeptide comprises at least one non-native cysteine residue at a site selected from the group consisting of T1CP2 (SEQ ID NO: 25), P2CL3 (SEQ ID NO: 26), L3CG4 (SEQ ID NO: 27), G4CP5 (SEQ ID NO: 28), P5CA6 (SEQ ID NO: 29), A6CS7 (SEQ ID NO: 30), S96CP97 (SEQ ID NO: 31), P97CE98 (SEQ ID NO: 32), L99CG100 (SEQ ID NO: 33), P101CT102 (SEQ ID NO: 34), E122CE123 (SEQ ID NO: 35), L124CG125 (SEQ ID NO: 36), M126CA127 (SEQ ID NO: 37), P138CA139 (SEQ ID NO: 39), A143CF144 (SEQ ID NO: 40), R146CR147 (SEQ ID NO: 41), R169CH170 (SEQ ID NO: 42), H170CL171 (SEQ ID NO: 43), L171CA172 (SEQ ID NO: 44), A172CQ173 (SEQ ID NO: 45), and Q173CP174 (SEQ ID NO: 46) in an amino acid sequence having at least 90% sequence identity to sequence set forth in SEQ ID NO: 2.